HONG KONG, August 28, 2026 – (ACN Newswire) – Cryofocus Medtech (Shanghai) Co., Ltd. (“Cryofocus” or the “Company,” stock code: 6922. HK), a leading ingenious medical gadget platform focusing on minimally-invasive interventional cryotherapy, today revealed its interim outcomes for the 6 months ended June 30, 2026. Throughout the Reporting Period, the Company continued to broaden its item pipeline, with a considerable 37.9% constricting of its loss for the duration to RMB 16.9 million. Gross revenue margin enhanced to 68.5% from 67.1% in the exact same duration in 2015, while money and money equivalents rose 69.2% to RMB 59.3 million compared to the end of 2025, highlighting boosted functional quality and monetary durability.

Item Pipeline Continues to Expand, Commercial Footprint Widens

As a leader in the field of minimally-invasive interventional cryotherapy in China, Cryofocus has actually developed a detailed item portfolio covering both vascular intervention and natural orifice transluminal endoscopic surgical treatment (NOTES). Since June 30, 2026, the Company had an overall of 25 items and item prospects, of which 11 had actually been advertised. These consist of the Atrial Fibrillation Cryoablation System, Malignant Stenosis Cryoablation System, Cryoadhesion System, Bladder Cryoablation System, and Pulmonary Nodule Localization Needle, to name a few.

In January 2026, the Company’s Endoscopic Additional Working Channel Catheter got approval from the Zhejiang Medical Products Administration, additional enhancing its industrial item matrix. A number of high-value item prospects have actually gotten in the important confirmatory scientific trial phase and are anticipated to get approvals sequentially in between 2027 and 2029. These consist of:

– Vascular Intervention:

Cryofocus Renal Denervation System (Cryo-RDN System): Designed to be the world’s very first cryoablation item particularly targeting high blood pressure. It was given Breakthrough Device classification by the U.S. FDA in December 2022.

– Breathing Intervention:

COPD Cryospray System, Peri-Pulmonary Nodule Cryoablation System, Asthma Cryoablation System, and Benign Stenosis Cryoablation System: These items form a matrix of investigational gadgets targeting the exact same healthcare facility department. As they get approvals in the coming duration, the synergistic impact of this item matrix is anticipated to enhance.

The Company’s R&D group consists of 40 experts. Since June 30, 2026, Cryofocus held 179 patents and 35 patent applications locally and worldwide, continually deepening its technological moat.

Loss Narrows Significantly, Gross Margin Improves Against Headwinds

Along with constant development in its item pipeline, the Company provided remarkable monetary metrics. For the very first half of 2026, Cryofocus taped earnings of RMB 40.7 million and gross revenue of RMB 27.9 million. The loss for the duration totaled up to RMB 16.9 million, a reduction of RMB 10.3 million or 37.9% from RMB 27.2 million in the very same duration of 2025.

Versus the background of an active modification in income scale, the Company’s total gross earnings margin increased from 67.1% to 68.5%, mainly driven by procedure enhancements and optimizations for particular items. This suggests that structural enhancements in the item mix and boosted production performance have actually successfully balanced out the effect of profits changes on success.

Comprehensive Cost Optimization Boosts Operating Efficiency Significantly

The considerable constricting of losses was underpinned by the Company’s holistic expense control steps:

– Administrative costsreduced by 34.0% from RMB 33.7 million to RMB 22.3 million, primarily due to decreases in personnel expenses and share-based payments.

– Offering and circulation expendituresfell by 14.5% from RMB 9.2 million to RMB 7.8 million.

– Research study and advancement costsdecreased by 15.1% from RMB 17.9 million to RMB 15.2 million.

– Financing costsstopped by 22.7% from RMB 1.1 million to RMB 0.8 million.

other earnings and gainsrose over 550% from RMB 0.5 million to RMB 3.2 million, mainly attributable to a boost in federal government grants. The combined impact of extensive expense optimization and development in non-recurring earnings allowed the Company to attain a sharp compression of losses in spite of a short-lived decrease in income.

Money Reserves Surge 69.2%, Strengthening Capital Position

Since June 30, 2026, the Company’s money and money equivalents stood at RMB 59.3 million, a boost of RMB 24.2 million or 69.2% from RMB 35.0 million since December 31, 2025. This development was generally driven by the conclusion of an H-share positioning in January 2026, under which the Company released 5,595,000 H-shares and raised net earnings of around HK$ 29.73 million.

In addition, the Company’s present ratio enhanced from 1.5 to 1.7, the fast ratio increased from 1.0 to 1.2, and the tailoring ratio reduced from 64.7% to 61.8%, showing improved short-term solvency and total monetary security.

Outlook: Committed to Becoming a Global Minimally-Invasive Interventional Cryotherapy Medical Device Platform, Bringing Benefits to Patients and Physicians Worldwide

In the very first half of 2026, the Company proactively changed its sales technique to line up with progressing market needs, resulting in a momentary dip in earnings. Incomes quality enhanced significantly, signifying a favorable pattern of “structural earnings modification with clear earnings flexibility.”

Looking ahead, the Company will:

– Rapidly advance the medical advancement and commercialization of its item prospects based upon cryotherapy innovation;

– Continue to concentrate on minimally-invasive interventional cryotherapy and additional broaden its item portfolio leveraging its innovation platform;

– Persistently research study and establish different underlying and supporting innovations; and

– Selectively broaden its worldwide footprint.

With high-value items such as the Cryofocus Renal Denervation System, COPD Cryospray System, and Peri-Pulmonary Nodule Cryoablation System getting in the regulative submission and launch cycle, combined with a considerably strengthened money position and constant loss decrease, Cryofocus is progressively speeding up towards its vision of ending up being a “international minimally-invasive interventional cryotherapy medical gadget platform.”

Subject: Press release summary